Concepts (50)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pyridines | 4 | 2003 | 116 | 0.360 |
Why?
|
| Allyl Compounds | 2 | 2012 | 47 | 0.210 |
Why?
|
| Benzo(a)pyrene | 2 | 2012 | 126 | 0.190 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2003 | 121 | 0.180 |
Why?
|
| Benzamides | 1 | 2003 | 78 | 0.100 |
Why?
|
| Disulfides | 1 | 2012 | 77 | 0.100 |
Why?
|
| Carcinogens | 1 | 2012 | 124 | 0.100 |
Why?
|
| Sulfides | 1 | 2012 | 62 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 172 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2003 | 149 | 0.090 |
Why?
|
| Plant Extracts | 1 | 2012 | 286 | 0.090 |
Why?
|
| Models, Molecular | 1 | 2003 | 808 | 0.080 |
Why?
|
| Carrageenan | 3 | 2003 | 12 | 0.070 |
Why?
|
| Edema | 3 | 2003 | 23 | 0.070 |
Why?
|
| Indomethacin | 2 | 2003 | 28 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2003 | 1618 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2003 | 289 | 0.050 |
Why?
|
| DNA Damage | 2 | 2012 | 352 | 0.040 |
Why?
|
| Structure-Activity Relationship | 2 | 2003 | 409 | 0.040 |
Why?
|
| Rats | 3 | 2003 | 3483 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2000 | 1039 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2012 | 2231 | 0.030 |
Why?
|
| Chromatography, Thin Layer | 1 | 2003 | 37 | 0.030 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2003 | 37 | 0.030 |
Why?
|
| Chemistry, Physical | 1 | 2003 | 45 | 0.030 |
Why?
|
| Chemical Phenomena | 1 | 2003 | 54 | 0.030 |
Why?
|
| Indicators and Reagents | 1 | 2003 | 58 | 0.030 |
Why?
|
| Garlic | 1 | 2012 | 30 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2012 | 35 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 2003 | 152 | 0.030 |
Why?
|
| Comet Assay | 1 | 2012 | 76 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2012 | 326 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 399 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 461 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2000 | 115 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2000 | 112 | 0.020 |
Why?
|
| Animals | 3 | 2003 | 15081 | 0.020 |
Why?
|
| Cell Survival | 1 | 2012 | 864 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 1 | 2000 | 128 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2000 | 220 | 0.020 |
Why?
|
| Excipients | 1 | 1998 | 22 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 433 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2000 | 316 | 0.020 |
Why?
|
| Male | 3 | 2003 | 20025 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2012 | 1198 | 0.020 |
Why?
|
| Macrophages | 1 | 2000 | 439 | 0.020 |
Why?
|
| Cell Line | 1 | 2000 | 1354 | 0.020 |
Why?
|
| Blood Glucose | 1 | 1998 | 353 | 0.020 |
Why?
|
| Apoptosis | 1 | 2012 | 1398 | 0.020 |
Why?
|
| Humans | 2 | 2012 | 37093 | 0.010 |
Why?
|